Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 2/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.46 |
| ▸ | WNT3A | P56704 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675994 | 0.83 | NEK2 (0.69) | NEK2ROCK2ROCK1MAPTRAB9A | |
| SCHEMBL29569257 | 0.79 | NOS1 (0.53) | NEK2ROCK2ROCK1MAPTRAB9A | |
| SCHEMBL182465 | 0.79 | NOS1 (0.53) | NEK2ROCK2ROCK1MAPTRAB9A | |
| SCHEMBL6599321 | 0.79 | ROCK2 (0.53) | NEK2ROCK2ROCK1MAPTRAB9A | |
| SCHEMBL25228737 | 0.78 | ESR1 (0.60) | NEK2 | |
| SCHEMBL1904668 | 0.77 | NEK2 (1.00) | NEK2ROCK2ROCK1MAPTKDM4E | |
| SCHEMBL12675980 | 0.77 | NEK2 (1.00) | NEK2ROCK2ROCK1MAPTKDM4E | |
| SCHEMBL12675976 | 0.77 | NEK2 (0.58) | NEK2ROCK2ROCK1MAPTRAB9A | |
| SCHEMBL12675878 | 0.77 | NEK2 (0.58) | NEK2ROCK2ROCK1MAPTRAB9A | |
| SCHEMBL1904666 | 0.77 | NEK2 (1.00) | NEK2ROCK2ROCK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | claimed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | claimed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | claimed |
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | disclosed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | NEK2 2324/4885ROCK2 3767/4885ROCK1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.